Axikin Pharmaceuticals
Axikin

Axikin Pharmaceuticals submits IND for AXP1275

July 20th, 2012 — Axikin Pharmaceuticals, Inc. submits an IND application to the FDA for Phase 1 study of AXP1275. The proposed Phase 1 study will investigate the safety and tolerability of AXP1275 in healthy volunteers and represents a novel class of orally-available allosteric modulators against the CCR3 chemokine receptor.

CCR3 and its cognate ligands are known to be up-regulated in allergic diseases including asthma, allergic rhinitis, eosinophilic oesophagitis and certain dermatoses. Classically associated with the trafficking and activation of eosinophils, Axikin’s research has demonstrated that CCR3 plays a role in mediating pro-inflammatory effects not only on the eosinophil but also, epithelial and endothelial cells in the lung parenchyma and thus may contribute to airways hyperreactivity as well as the leukocytic inflammatory component of allergic and non-allergic asthma. In non-human primate models of allergic asthma, Axikin’s inhibitors to CCR3 have been shown to reduce airways hyperreactivity and inflammation and may therefore be highly useful as monotherapies for asthmatic individuals.

Axikin has developed a highly potent and selective portfolio of CCR3 inhibitors devoid of the safety and toxicological liabilities that have plagued this field for other CCR3 antagonists and inhibitors. The Phase I study is the first of a series of planned studies that Axikin hopes to lead to the demonstration of the effectiveness of this strategy in controlling the asthmatic response.

About Axikin Pharmaceuticals Inc.:
Axikin Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused exclusively on the development and commercialization of small molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Axikin was spun out from Actimis Pharmaceuticals, in June 2008. Investors include Sanderling Ventures and Mitsui & Co. Venture Partners.

Axikin Pharmaceuticals Inc.
Kevin Bacon, Ph.D.

6185 Cornerstone Ct., Suite 106
San Diego, CA 92121
USA
Phone:+1 (858) 458 - 1890
Fax: +1 (858) 642 - 6962
E-Mail: kbacon@axikin.com
www.axikin.com

 

 

Media Contact
Karen Sparks

Mentus
858-455-5500 x275
858-458-1890
karen@mentus.com

Company Contact
Kevin Bacon, Ph.D.
6185 Cornerstone Ct.
Suite 106
San Diego, CA 92121
Phone: (858) 458-1890
kbacon@axikin.com

 

driven by rightturn